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Abstract
Dengue is the most prevalent arboviral infection, affecting millions of people every year. Attempts to control such infection
are being made, and the development of a vaccine is a World Health Organization priority. Among the proteins being tested
as vaccine candidates in preclinical settings is the non-structural protein 1 (NS1). In the present study, we tested the
immune responses generated by targeting the NS1 protein to two different dendritic cell populations. Dendritic cells (DCs)
are important antigen presenting cells, and targeting proteins to maturing DCs has proved to be an efficient means of
immunization. Antigen targeting is accomplished by the use of a monoclonal antibody (mAb) directed against a DC cell
surface receptor fused to the protein of interest. We used two mAbs (aDEC205 and aDCIR2) to target two distinct DC
populations, expressing either DEC205 or DCIR2 endocytic receptors, respectively, in mice. The fusion mAbs were
successfully produced, bound to their respective receptors, and were used to immunize BALB/c mice in the presence of
polyriboinosinic: polyribocytidylic acid (poly (I:C)), as a DC maturation stimulus. We observed induction of strong anti-NS1
antibody responses and similar antigen binding affinity irrespectively of the DC population targeted. Nevertheless, the IgG1/
IgG2a ratios were different between mouse groups immunized with aDEC-NS1 and aDCIR2-NS1 mAbs. When we tested the
induction of cellular immune responses, the number of IFN-c producing cells was higher in aDEC-NS1 immunized animals.
In addition, mice immunized with the aDEC-NS1 mAb were significantly protected from a lethal intracranial challenge with
the DENV2 NGC strain when compared to mice immunized with aDCIR2-NS1 mAb. Protection was partially mediated by
CD4+ and CD8+ T cells as depletion of these populations reduced both survival and morbidity signs. We conclude that
targeting the NS1 protein to the DEC205+ DC population with poly (I:C) opens perspectives for dengue vaccine
development.
Citation: Henriques HR, Rampazo EV, Gonc¸alves AJS, Vicentin ECM, Amorim JH, et al. (2013) Targeting the Non-structural Protein 1 from Dengue Virus to a
Dendritic Cell Population Confers Protective Immunity to Lethal Virus Challenge. PLoS Negl Trop Dis 7(7): e2330. doi:10.1371/journal.pntd.0002330
Editor: Mary Ann McDowell, University of Notre Dame, United States of America
Received November 22, 2012; Accepted June 12, 2013; Published July 18, 2013
Copyright:  2013 Henriques et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by the Brazilian National Research Council (CNPq)/National Institutes of Science and Technology in Vaccines (INCTV,
15203*12), Sa˜o Paulo State Research Funding Agency (FAPESP, 2007/08648-9, 2011/51761-6), BNP-Paribas Bank and Rio de Janeiro State Research Funding
Agency (FAPERJ). HRH and JHA received fellowships from FAPESP (2010/03079-9 and 2009/5033-7) and EVR received a fellowship from CAPES. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sbboscardin@usp.br
. These authors contributed equally to this work.
Introduction
Dengue fever is a mosquito-borne disease caused by four
distinct viral serotypes (DENV1, 2, 3 and 4) [1,2]. Over the past
few decades, the alarming growth in the number of cases as well as
the increase in the incidence of more serious clinical forms of the
disease, the dengue hemorrhagic fever (DFH) or the dengue shock
syndrome (DSS), have led the World Health Organization to
prioritize the development of a dengue vaccine [1,2]. Various
formulations and vaccine antigens are currently under clinical
evaluation or preclinical development [3–5]. Among the virus
proteins that can induce protective immunity in experimental
conditions is the non-structural protein 1 (NS1). NS1 is a 43–48 kDa
glycoprotein expressed in infected cells and present on the cell
membrane in dimeric form, but can also be secreted in dimeric
and hexameric forms [6–8]. Anti-NS1 antibodies, which are
normally detected at the beginning of a dengue infection, along
with the secreted protein, are currently used in disease diagnosis
[8,9]. Anti-NS1 antibodies generated in infected individuals have
been demonstrated to fix complement components leading to
elimination of infected cells [10]. On the other hand, others have
shown that anti-NS1 antibodies can cross react with platelets and
endothelial cells and, thus, interfere with platelet aggregation and
cause endothelial cell damage [11–13]. Despite the conflicting
reports regarding the role of NS1 in the prevention of the disease,
promising results were obtained with vaccine formulations
PLOS Neglected Tropical Diseases | www.plosntds.org 1 July 2013 | Volume 7 | Issue 7 | e2330
containing recombinant proteins produced in bacteria [14],
baculovirus [15] or encoded by DNA vaccines [16–18]. Different
degrees of protection were observed depending on the vaccine
formulation, and protective immunity seemed to be dependent on
NS1-specific antibody and/or T cell responses [14,16–18].
In an attempt to improve both cellular and humoral immune
responses against DENV NS1, we evaluated a vaccine strategy in
which the target antigen is delivered to dendritic cells (DCs). DCs
are professional antigen presenting cells that link innate and
adaptive immune responses [19–21]. An increasing amount of
evidence has shown that the immunogenicity of proteins can be
improved by delivering them to DCs [22–30]. Such specific cell
targeting can be accomplished after genetic fusion of the protein to
the C-terminal portion of a monoclonal antibody (mAb) with
specificity for a DC surface receptor [31]. The administration of
the recombinant mAb in the presence of an appropriate agonist
for DC maturation increases the efficiency of antigen presentation
on MHC class I and II molecules and induces T-cell help for
antibody responses [23,28,32].
There are several DC populations in steady state [33]. Based on
cell surface markers (like CD11c) and in biological functions, there
are two major resident DC populations in mouse secondary
lymphoid organs: the first expresses the CD8a chain and a C-type
lectin endocytic receptor known as DEC205/CD205 (CD8a+-
DEC205+), while the second lacks the CD8a and expresses
another C-type lectin receptor known as DCIR2 (CD8a2D-
CIR2+) [34]. CD8a+ and CD8a2 DCs seem to have different
functions. For example: CD8a+ DCs are able to capture dying
cells [35,36] and cross-present exogenous antigens on MHC class I
[37–39] besides being the major IL-12 producers upon activation
[40]. On the other hand, CD8a2 DCs elicit IL-4 and more
efficiently form peptide MHC II complexes [26,34,41].
In the last decade, the capacity of DEC205 and DCIR2 to
efficiently mediate antigen presentation in vivo was demonstrated
by injecting the corresponding anti-receptor mAbs fused to
proteins derived from different pathogens [23,25–
28,32,34,42,43]. The delivery of vaccine proteins fused to the
aDEC mAb increased the efficiency of antigen presentation and
allowed protein-based vaccines to induce large numbers of Th1
type CD4+ T cells and antibody secreting B cells
[23,25,27,28,32,43–45], as well as CD4+ T cell dependent
protection to challenge in some systems [27,32]. Antigen targeting
through the DCIR2 receptor was able to induce proliferation of
CD4+ T cells [26,34] and also led to robust class-switched
antibody responses to T cell-dependent antigens [30]. In one case,
the antibodies induced by targeting the protein to DCIR2 were
able to protect mice against pneumonic plague [42].
In the present study, we generated recombinant DENV2 NS1
genetically fused to the aDEC or aDCIR2 mAbs and used them to
immunize mice in the presence of the toll-like receptor (TLR) 3
and melanoma differentiation-associated gene-5 (MDA5) agonist
poly (I:C), as a DC maturation stimulus. Our results show that
immunization of mice with these mAbs induced high anti-NS1
antibody titers that were, at least in part, directed against
conformational epitopes. Despite differences in the IgG subclass
responses, we did not observe any significant difference in the
affinities of the anti-NS1 antibodies in vaccinated mice. More
importantly, targeting NS1 to the CD8a+ DC population through
the DEC205 receptor induced a significantly higher number of
IFN-c producing cells and conferred protection to virus mortality
and morbidity that was attributed to the generation of antigen-
specific CD4+ and CD8+ T cell responses.
Materials and Methods
Mice
Six- to 8-week-old adult male BALB/c mice were bred under
specific- pathogen free conditions at the Isogenic Mouse Facility of
the Parasitology Department, University of Sa˜o Paulo, Brazil. All
animals were used according to the Brazilian College of Animal
Experimentation (CONEP) guidelines, and the protocols were
approved by the Institutional Animal Care and Use Committee
(CEUA) of the University of Sa˜o Paulo (protocol number 082) and
by the Animal Use Ethical Committee of Fundac¸a˜o Oswaldo Cruz
(approval ID: L-067/08).
Plasmid generation
The cDNA encoding the DENV2 NGC strain NS1 sequence
was obtained from plasmid pcENS1 [16] and cloned in frame with
the carboxyl terminus of the heavy chain of mouse aDEC205
(NLDC145 clone) or aDCIR2 (33D1 clone) antibodies (kindly
provided by Dr. Michel C. Nussenzweig, The Rockefeller
University), as previously described [23,28,31,34]. Amplification
was accomplished using the Phusion High Fidelity DNA
Polymerase (New England Biolabs) according to the manufactur-
er’s instructions. The following primers were used: sense
(59-GCTCGAGGAGTTCGGTAGGTTCGATAGTGGTTGC-
GTTGTGAG-39) and anti-sense (59-GGCGGCCGCTCAGGC-
TGTGACCAAGGAGTTG-39). Plasmids pDEC-NS1 and
pDCIR2-NS1 were then generated and sequenced to confirm
the presence of NS1 in frame.
Expression of recombinant fusion antibodies
Plasmids containing the heavy chain of the mouse aDEC205 or
aDCIR2 antibodies (pDEC-NS1, pDEC, pDCIR2-NS1 or
pDCIR2) and their respective light chains (pDEC kappa or
pDCIR2 kappa, kindly provided by Dr. Michel C. Nussenzweig,
The Rockefeller University) were used to transform DH5a
bacteria. A single bacterial clone containing each plasmid was
grown for 16–18 h at 37uC under 200 rpm shaking in 200 ml of
LB medium (Life Technologies) containing 100 mg/ml ampicillin
(Sigma). Plasmid DNA was purified with QIAGEN Maxi Prep
columns (Qiagen), according to the manufacturer’s instructions.
Human embryonic kidney (HEK) 293T (ATCC No CRL-
11268) cells were cultured in 150 mm plates (TPP) under standard
conditions in Dulbecco’s Modified Eagle’s Medium (DMEM; Life
Technologies) supplemented with 5% ultra-low heat inactivated
fetal bovine serum (FBS, Life Technologies), 16 l-glutamine and
16 antibiotic-antimycotic (all from Life Technologies). When cell
Author Summary
Dengue is one of the most prevalent viral infections. It
affects millions of people every year and can be life-
threatening if left untreated. The development of a
dengue vaccine is a public health priority. In the present
study, we decided to use a dengue virus derived protein,
named non-structural protein 1 (NS1) in an immunization
protocol that targets the antigen to dendritic cells (DCs).
DCs are central for the induction of immunity against
pathogens and there are a few DC populations already
described. NS1 was engineered in fusion with two distinct
monoclonal antibodies that are capable of binding two
different receptors present on the surface of these cells.
NS1 targeting to one DC population (known as DEC205+)
was able to induce anti-NS1 immune responses and confer
protection to mice challenged with serotype 2 dengue
virus.
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confluence reached 70–80%, FBS-supplemented DMEM was
washed off and replaced by 20 mL of DMEM supplemented with
1% Nutridoma-SP (Roche), 16 l-glutamine and 16 antibiotic-
antimycotic prior to polyethyleneimine (PEI)-mediated transfec-
tion with equal amounts of the corresponding heavy and light
chain vector DNAs [46]. Ten mg of each vector DNA was added to
a final volume of 1 mL 150 mM NaCl solution containing 4.5 mg
of PEI per mg of DNA. The mix was vortexed for 10 secs,
incubated for 10 min at room temperature and distributed evenly
to the culture plate. Culture supernatants from 25 plates were
harvested 5–6 days after transfection, cleared from cell debris by
centrifugation at 1,0006g for 30 min and filtered in 0.22 mM
membranes (Corning). The antibodies present in the supernatants
were precipitated by addition of ammonium sulfate (Amresco) to
60% (weight:volume) of the total culture volume. The mixture was
stirred overnight at 4uC and then centrifuged at 10,0006g for
30 min at 4uC. The precipitated antibodies were resuspended in
50 mL of cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4) containing 1 mM PMSF (Amresco),
and dialysed against 2 L of cold PBS. Recombinant fusion
antibodies were purified with Protein G beads (GE Healthcare)
by incubation of 500 ml Protein G beads per 50 ml resuspended
cell culture supernatants overnight at 4uC and under rotation.
Supernatants were removed after centrifugation at 8006g for
10 min at 4uC. Beads were resuspended in cold PBS and
transferred to a chromatography spin column (BioRad) previously
equilibrated with PBS. After two rounds of washes with 5 ml cold
PBS, antibodies were eluted in 5–6 fractions (500 ml each) with
glycine 0.1 M (pH 3.0). Eluates were collected in tubes containing
50 ml Tris 1 M (pH 8.0) for pH neutralization. The fractions
containing antibodies were pooled together and dialysed against
2 L cold PBS, filtered through 0.2 mM membranes (TPP) for
sterilization and finally had their concentrations estimated by the
Bradford assay (Pierce). Aliquots were then stored at 220uC until
use.
Western blots
Approximately 1 mg of each fusion antibody or the recombinant
dimeric NS1 [47] were ran on 7 or 12% SDS-PAGE gels under
non-reducing or reducing conditions, respectively. Gels were
either stained with Coomassie Blue (Amresco) or transferred to
nitrocellulose membranes (GE Healthcare). Membranes were
blocked (PBS-Tween 20 0.05%, non-fat milk 5% and BSA 1%) for
1 hour at room temperature. Membranes containing non-reduced
antibodies were incubated with an anti-NS1 polyclonal antibody
raised against the dimeric form of NS1 [47] in a 1:2,000 dilution.
After washes with 0.05% PBS-T, membranes were incubated with
horseradish peroxidase (-HRP)-anti-mouse IgG2a (1:3,000; South-
ernBiotech) for 1 h at room temperature and developed using
chemiluminescence (ECL kit, GE Healthcare). Differently, mem-
branes containing the reduced antibodies were incubated with
goat anti-mouse IgG Fc specific-HRP (1:5,000, Jackson Labora-
tories) plus goat anti-mouse IgG kappa-HRP (1:3,000; South-
ernBiotech). Washes and development were performed as
described for the reduced membranes.
Binding assays
Binding assays were performed using CHO cells expressing
either the mouse DEC205 or the mouse DCIR2 receptors [42],
kindly provided by Dr. Michel Nussenzweig (The Rockefeller
University) or using freshly isolated splenocytes from naı¨ve mice.
One hundred and fifty thousand CHO cells stably expressing
either the DEC205 or the DCIR2 receptor were incubated with
10, 1 or 0.1 mg/mL of each fusion antibody on ice for 45 min.
After two washes with PBS - 2% fetal bovine serum (FBS, Life
Technologies), cells were incubated with anti-mouse IgG1-PE
(1:2,000) for 30 minutes on ice. After 2 additional washes, 20,000
events were acquired using FACSCalibur flow cytometer (BD
Biosciences).
Additionally, each fusion mAb was tested for its capacity to bind
to either CD11c+CD8a+ or CD11c+CD8a2 DCs. Splenocytes
from naı¨ve mice were harvested and suspended in PBS-FBS 2%.
Five million cells were initially incubated with anti-CD16/32 (Fc
block) for 15 min and then incubated with 10, 1 or 0.1 mg/mL of
each fusion antibody on ice for 45 min. After 2 washes, anti-mouse
IgG1-PE, anti-CD11c-APC, anti-DX5-biotin, anti-CD19-biotin,
anti-MHCII-FITC and anti-CD8-PE-Cy7 were added for 45 min
on ice. After another round of washes, cells were incubated with
streptavidin-PerCP (BD biosciences). All mAbs were purchased
from BD biosciences. Half a million events were acquired using
FACS Canto flow cytometer (BD biosciences). All analyses were
performed using FlowJo software (version 9.3, Tree Star, San
Carlo, CA).
Immunizations and challenge
Groups of 4–10 animals received 2 doses with a 28-day interval
of 5 mg of each fusion mAb administered intraperitoneally (i.p.)
together with 50 mg poly (I:C) (Invivogen). Control groups were
also immunized with poly (I:C) alone or with 10 mg of
recombinant NS1 protein produced as previously described [47]
plus poly (I:C). Four days before or 14 days after the boost, mice
were bled by retro-orbital puncture and serum was obtained.
Twenty days after the boost, mice were challenged with the mouse
brain adapted NGC DENV2 strain, as previously described [17].
In some experiments, immunized mice were injected i.v. with
100 mg of aCD4 (clone GK1.5) or aCD8 (clone 2.43) mAbs to
deplete CD4 and CD8 T cell populations one day before the
challenge. For the challenge assays, animals were anesthetized
with a mixture of ketamine-xylazine and then inoculated by the
intracerebral route (i.c.) with 30 mL of DENV2 NGC strain
corresponding to approximately 40 LD50 [48]. After the challenge,
mice were monitored daily for 21 days for signs of morbidity
according to the following scale: 0 = no signs of paralysis or spinal
cord alteration, 1 = mild paralysis in one hind leg or alteration of
the spinal column with a small hump, 2 = severe paralysis in one
hind leg and alteration of the spinal column with a small hump or
severe paralysis in both hind legs, 3 = two severe hind leg paralysis
and deformed spinal column, 4 = death [49]. After that period,
animals that survived challenge were sacrificed.
Analysis of NS1-specific antibodies
For the detection of NS1-specific antibodies, ELISA assays were
performed as described previously [23]. Briefly, high-binding
ELISA plates (Costar) were coated overnight with 200 ng/well
refolded recombinant NS1 protein [47] in PBS. Plates were then
washed 3 times with PBS-Tween 20 0.02% and blocked with PBS-
Tween 20 0.02%, non-fat milk 5% and BSA 1% for 1 h at room
temperature. Serial dilutions of the sera in PBS-Tween 20 0.02%,
non-fat milk 5% and BSA 0.25% were incubated for 2–3 h at
room temperature. The secondary antibodies used were goat anti-
mouse IgG Fc-specific-HRP (1:5,000; Jackson ImmunoResearch
Laboratories) or anti-mouse IgG subclass-HRP specific antibodies
(1:3,000; SouthernBiotech). After three additional washes, plates
were developed with ortho-phenylenediamine dihydrochloride
(Sigma) and H2O2 as substrate and with 4 N H2SO4 as stop
solution. OD490 was measured using a microplate reader (Biotek).
Titers represent the highest serum dilution showing an OD490
.0.1 normalized in a log10 scale. The IgG1/IgG2a ratio was
Targeting Dengue Antigens to Dendritic Cells
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calculated by dividing the mean values of the highest serum
dilution obtained for IgG1 by the mean value of the highest serum
dilution obtained for IgG2a without normalization. Anti-NS1
antibody affinities were determined by a thiocyanate elution-based
ELISA [50] as described by Rosa et al. [51] using pooled sera in
triplicates. The percentage of binding was calculated considering
the following formula: (OD490 in the presence of ammonium
thiocyanate X 100)/(OD490 in the absence of ammonium
thiocyanate).
Analysis of the cellular immune response
Spleen cell isolation. Mice were euthanized with CO2 seven
days after the second immunization and spleens were removed
aseptically. Bulk splenocytes were obtained in suspension and
washed once with RPMI 1640 (Sigma). Red blood cells were lysed
with 1 mL ACK solution (150 mM NH3Cl, 10 mM KHCO3,
0.1 mM EDTA) per spleen for 2 minutes at room temperature.
After two additional washes with RPMI 1640, splenocytes were
resuspended in R10 (RPMI supplemented with 10% of fetal
bovine serum (GIBCO), 2 mM L-glutamine (GIBCO), 10 mM
Hepes (GIBCO), 1 mM sodium pyruvate (GIBCO), 1% vol/vol
non-essential aminoacid solution (GIBCO), 1% vol/vol vitamin
solution (GIBCO), 20 mg/mL of ciprobacter (Isofarma, Brazil) and
561025 M 2-mercaptoetanol (GIBCO)). Cell viability was eval-
uated using 0.1% Trypan Blue exclusion dye and cell concentra-
tion was estimated using a hemocytometer.
IFN-c ELISPOT. ELISPOT assays for the detection of IFN-c
producing splenocytes were performed using the Ready-SET-Go
kit (eBioscience), according to the manufacturer’s instructions.
Briefly, ELISPOT plates (MAIPS; Millipore) were coated with the
capture antibody overnight at 4uC. After two washes with the
Coating Buffer, plates were blocked with R10 for at least 1 h at
room temperature. Splenocytes were cultured for 18–20 hours at
37uC with 5% CO2 in the presence of 1 mg/mL recombinant NS1
protein or with the ovalbumin protein (grade II, Sigma), as a non-
related protein. Plates were then washed with PBS Tween 20
0.05% and incubated with the biotinylated anti-IFN-c antibody
for 2 h at room temperature. After 4 more washes, the plates were
incubated with avidin–horseradish peroxidase for 1 h at room
temperature. Spots were visualized with the AEC kit (BD
biosciences) and counted using an automated stereomicroscope
(KS ELISPOT, Zeiss, Oberkochem, Germany). The number of
IFN-c producing cells/106 splenocytes was calculated after
subtracting the negative control values (number of cells in the
wells containing medium only).
Data analysis
Statistical significance (p-values) was calculated using one-way
ANOVA and Tukey’s honestly significantly different (HSD). Log-
rank test was used to compare mouse survival times after
challenge. All tests were calculated using Prism 5 software
(GraphPad Software Inc, LA Jolla, CA). Differences with
p#0.05 were considered statistically significant.
Results
Generation of mAbs fused to NS1
For the generation of the fusion aDEC-NS1 or aDCIR2-NS1
mAbs, we fused the open reading frame of the sequence encoding
the DENV2 NS1 protein of the NGC strain to the sequences
corresponding to the C-terminal portion of aDEC or aDCIR2
heavy chains (data not shown). As controls, we also produced the
aDEC and aDCIR2 antibodies without any fused antigen. All
mAbs were purified and their integrity was evaluated by SDS-
PAGE under non-reduced and reduced conditions (Figure 1).
Figure 1A shows that heavy and light chains of the purified mAbs
had the expected electrophoretic motilities (,95 and 25 kDa,
respectively, for the fusion antibodies and ,50 and 25 kDa, for
the controls) under reducing conditions. Under non-reducing
conditions, the presence of multiple bands when aDEC-NS1 and
aDCIR2-NS1 were separated by electrophoresis suggested the
formation of multimers (Figure 1B). Figure 1C shows that specific
anti-mouse antibodies for the immunoglobulin light and heavy
chains recognized the recombinant mAbs. Finally, we also
demonstrated (Figure 1D) that antibodies raised against DENV2
NS1 protein recognized its monomeric and dimeric forms and
only the fusion mAbs, suggesting that fusion with the aDEC or
aDCIR2 did not change conformational epitopes of the NS1
protein.
The fusion mAbs bind specifically to cells expressing
either DEC205 or DCIR2 receptors
The fusion mAbs maintained their capacity to bind to their
respective receptors when different concentrations (10, 1 or
0.1 mg/mL) were incubated with CHO cells expressing either
DEC205 or DCIR2 receptors, or with DCs CD11c+CD8a+ or
CD11c+CD8a2 (gating strategy depicted in Figure S1). Results
show that the aDEC-NS1 mAb bound in a dose dependent
manner to CHO cells expressing the DEC205 receptor (Figure 2A,
left panel) or to CD11c+CD8a+ DCs (Figure 2B, left panel). On
the other hand, the aDCIR2-NS1 mAb bound, also in a dose
dependent manner, to CHO cells expressing the DCIR2 receptor
(Figure 2A, right panel) and to CD11c+CD8a2 DCs (Figure 2B,
right panel).
Analysis of the anti-NS1 antibody response after the
administration of two doses of the fusion mAbs in the
presence of poly (I:C)
BALB/c mice were immunized with two doses of each mAb
(aDEC-NS1, aDCIR2-NS1, aDEC or aDCIR2) in the presence of
poly (I:C), a TLR 3 and MDA5 ligand that has been used
successfully in combination with other aDEC fusion antibodies
[27,42]. Poly (I:C) has been previously compared to other TLR
ligands and was shown to be the most effective, at least for induction
of Th1 CD4+ T cell responses [52]. Additionally, a group of mice
received 10 mg of the recombinant NS1 protein in poly (I:C) which
corresponds to 5.7 times more protein than the amount delivered in
5 mg of either aDEC-NS1 or aDCIR2-NS1. Figure 3A depicts the
immunization protocol indicating when the mice were primed,
boosted, bled, euthanized or challenged. The presence of anti-NS1
antibodies in the sera of the immunized animals was evaluated by
ELISA, using a recombinant dimeric NS1 protein [47] 4 days
before or 14 days after the administration of the booster dose
(Figure 3B). Targeting the NS1 protein to either DEC205+ or
DCIR2+ DC populations induced high anti-NS1 serum IgG titers
particularly after the booster dose (p,0.01). However, no differ-
ences in the post boost anti-NS1 antibody titers were seen in mice
immunized with the two fusion mAbs indicating that, in the
presence of poly (I:C), NS1 targeting to either DEC205+ or DCIR2+
DC populations drives high antibody responses. The analysis of the
primary anti-NS1 response showed significantly higher anti-NS1
titers in the mice immunized with aDCIR2-NS1 when compared to
aDEC-NS1 (p,0.05). Higher anti-NS1 antibody titers were
observed in mice immunized with the recombinant NS1 protein
administered with poly (I:C) when compared to both aDEC-NS1
and aDCIR2-NS1 immunized groups either before (p,0.01) or
after (p,0.01) the boost. In contrast, serum from mice immunized
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with aDEC or aDCIR2 did not recognize NS1 protein demon-
strating the absence of unspecific responses.
To evaluate if the antibodies raised against NS1 were able to
recognize conformational epitopes, ELISAs were performed using
the boiled (heat-denatured) NS1 protein (Figure 3C). In fact,
protein denaturation led to a decrease in the anti-NS1 antibody
reactivity in all immunized groups (aDEC-NS1, aDCIR2-NS1 or
recombinant NS1) when compared to the response obtained
against the intact NS1 protein (p,0.01). This result indicated that
some of the anti-NS1 antibodies generated in mice immunized
with the fusion mAbs were directed against conformational
epitopes. Under such conditions, mice immunized with the
aDEC-NS1 showed a significantly lower response to the boiled
NS1 protein than mice immunized with either the aDCIR2-NS1
(p,0.01) or recombinant NS1 (p,0.01), suggesting that the
former fusion mAb induced a higher proportion of antibodies
targeting conformational epitopes. In fact, the smaller reduction in
the titers against the denatured protein in the animals immunized
with the recombinant NS1 indicates that this immunization
protocol probably induced more antibodies targeting linear
epitopes. As observed in Figure 3B, no anti-NS1 titers were
detected in mice immunized with the non-fused mAbs.
To further characterize the antibody responses, we determined
the NS1-specific IgG subclass responses in vaccinated mice
(Figure 4A). This analysis indicated that immunization with both
fusion mAbs (aDEC-NS1 or aDCIR2-NS1) or with the recom-
binant NS1 protein induced antibodies of all four IgG subclasses
(IgG1, IgG2a, IgG2b, and IgG3). Moreover, when the IgG1/
IgG2a ratios were calculated a clear difference between the
responses elicited in mice immunized with the two recombinant
mAbs was observed. While an IgG1/IgG2a ratio of 0.40 was
observed in mice immunized with the aDEC-NS1 mAb, a ratio of
3.71 was measured in mice immunized with the aDCIR2-NS1
mAb. These results further support the evidence that antigen
targeting to different DC populations modulates the induced
antibody responses [42]. Interestingly, immunization with recom-
binant NS1 and poly (I:C) resulted in an IgG1/IgG2a ratio similar
to that observed in mice immunized with the aDEC-NS1 mAb.
We cannot rule out the possibility that some of the recombinant
NS1 protein is being taken up by the DEC205+ DCs.
We have also measured the affinity of the anti-NS1 antibodies
generated in mice immunized with the fusion mAbs or with the
recombinant protein. The results indicated that the anti-NS1
antibody affinity did not change regardless of the targeted DC
Figure 1. Production and characterization of aDEC-NS1 and aDCIR2-NS1 mAbs. Approximately 1 mg of each mAb was separated under
reduced (A) and non-reduced (B) conditions. Both gels were stained with Coomassie Blue dye. The heavy (HC) and light (LC) chains of the following
antibodies are shown: 1) aDEC, 2) aDCIR2, 3) aDEC-NS1, 4) aDCIR2-NS1. (C) Western blotting using anti-mouse IgG and anti-mouse kappa chain
conjugated to HRP to verify the recognition of both heavy and light chains of each antibody. The numbers indicate the same order as in (A). (D)
Western blotting on a non-reduced gel using a mouse serum raised against the dimeric form of NS1 followed by protein A conjugated to HRP.
Columns 1–4, same as (A), column 5 contains 1 mg of NS1 produced in bacteria (Di_NS1: dimeric NS1 and Mo_NS1: monomeric NS1). Specific reaction
was obtained only in columns containing NS1. MW, molecular weight marker in kDa.
doi:10.1371/journal.pntd.0002330.g001
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population (Figure 4B). Also, no difference in affinity was detected
between the group immunized with NS1 plus poly (I:C) and the
ones immunized with both fusion mAbs (Figure 4B).
Analysis of the cellular immune responses in mice
immunized with the fusion mAbs in the presence of poly
(I:C)
The protocol described in the previous section was also used to
test if the immunization with both fusion mAbs induced cellular
immune responses to the DENV2 NS1. To test that possibility, we
performed an ELISPOT assay to detect IFN-c producing cells
(Figure 5). Our results show that NS1 protein targeting to the
DEC205+ DC population increases the number of NS1 specific
IFN-c producing cells when compared to the targeting to the
DCIR2+ DC population. In contrast, negligible numbers were
seen in mice immunized only with poly (I:C). This result supports
previous data that, in the presence of poly (I:C), antigen targeting
to the DEC205+ DC population increases the number of IFN-c
producing cells when compared to antigen targeting to the
DCIR2+ population [25,42].
Protective anti-DENV2 responses in mice immunized
with the fusion mAbs
The protective responses elicited in immunized mice were
evaluated after challenges carried out with 40 LD50 of the DENV2
NGC strain. As shown in Figure 6A, more than 60% of mice
immunized with the aDEC-NS1 mAb survived a lethal challenge.
In contrast, immunization with aDCIR2-NS1 mAb protected
12.5% of the mice. When animals were immunized with 10 mg of
the recombinant NS1 and poly (I:C), 50% survived the challenge.
This result is in agreement with previous results in which mice were
immunized with the same amount of recombinant NS1 and another
adjuvant (a genetically detoxified heat-labile toxin) [14]. In addition,
a significant reduction in morbidity signs was detected in mice
immunized with aDEC-NS1 mAb (37.5% of morbidity signs690%
in the aDCIR2-NS1 mAb immunized group, p,0.05), while no
difference was observed between the groups immunized with
aDEC-NS1 mAb and recombinant NS1 (Figure 6B and Figure
S2A). Noticeably the amount of NS1 delivered by the aDEC-NS1
mAb was 5.7 times lower than the amount of recombinant NS1
administered. In summary, targeting NS1 protein to the DEC205+
Figure 2. The fusion aDEC-NS1 and aDCIR2-NS1 mAbs bind to the DC DEC205 and DCIR2 receptors, respectively. (A) A density of 105
CHO cells expressing either DEC205 or DCIR2 receptors were incubated on ice with 10, 1 or 0.1 mg/mL of aDEC-NS1 or aDCIR2-NS1 fusion antibodies.
Binding was detected on 30.000 cells using an anti-mouse IgG1 antibody. (B) A density of 56106 splenocytes were incubated on ice with the same
concentrations of the fusion antibodies described in (A). Gates on CD11c+CD8a+ (DEC205 rich population) or CD11c+CD8a2 (DCIR2 rich population)
are shown in figure S1. Binding was detected on 16106 cells using an anti-mouse IgG1 antibody. One experiment representative of three is shown.
doi:10.1371/journal.pntd.0002330.g002
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DC population significantly reduced mortality and morbidity
associated with the virus challenge in the vaccinated mice.
To further investigate the mechanisms underlying the protective
response induced in mice immunized with the aDEC-NS1 mAb,
CD8+ and CD4+ T cell populations were depleted with specific anti-
CD4 or anti-CD8 mAbs one day prior to the virus challenge. In an
independent experiment, immunization with aDEC-NS1 mAb
achieved 75% protection from death. Depletion of the CD4+ T
cell population reduced survival to only 25% while depletion of
CD8+ T cells reduced survival to 37.5% (Figure 7A). Depletion of
CD4+ and CD8+ T cell populations also affected morbidity. All mice
depleted of the CD4+ T cell population and 62.5% depleted of CD8+
Figure 3. Induction of anti-NS1 antibody responses in mice immunized with the fusion aDEC-NS1 and aDCIR2-NS1 mAbs. (A)
Immunization protocol describing the order of immunizations, bleedings and challenge. Mice were immunized i.p. with 2 doses of 5 mg of each
fusion antibody in the presence of 50 mg of poly (I:C) or 10 mg of recombinant NS1 co-administered with 50 mg of poly (I:C). (B) Anti-NS1 antibody
titers 4 days before (white symbols) or 14 days after (black symbols) the administration of the second dose. (C) Anti-NS1 antibody titers obtained 14
days after the second dose were detected using intact (white symbols) or boiled (black symbols) NS1 protein. Symbols represent individual mice and
horizontal lines represent the mean value for each group. Fusion antibodies used for immunizations are depicted below. Data were analyzed by a
one-way ANOVA followed by the post-test HSD Tukey. P-value indicators * and *** refer to p,0.05 and p,0.01, respectively, while ns = not
significant.
doi:10.1371/journal.pntd.0002330.g003
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T cells showed some degree of morbidity, while only 25% of the mice
immunized with the aDEC-NS1 mAb presented morbidity signs
(Figure 7B and Figure S2B). These results suggest that, in our model,
both CD4+ and CD8+ T cells play important roles on the protective
immunity induced in mice immunized with aDEC-NS1 mAb.
Discussion
The search for an effective and safe vaccine formulation capable
of preventing morbidity and mortality associated with dengue
virus infection is a worldwide priority. Anti-dengue vaccine
formulations based on purified recombinant proteins, although
safer, are usually less immunogenic than vaccines based on
attenuated or recombinant viruses. The present study demon-
strated that targeting the NS1 protein to a DC population, using a
genetic fusion with a mAb that binds specifically to the DEC205
receptor, promoted an enhancement of both antibody levels and
cellular immune responses in mice. Furthermore, BALB/c mice
immunized with two doses of the recombinant aDEC-NS1 mAb
in the presence of poly (I:C) developed higher protection against a
lethal challenge than the protection obtained when animals were
immunized with 5.7 times more recombinant NS1 protein. This
protection involved CD4+ and CD8+ T cells, as mortality and
morbidity induced by the NGC DENV2 strain were increased in
the absence of such cells. Altogether the present study indicates
that targeting dengue virus proteins to a specific DC population
represents a novel and promising alternative to achieve safer and
effective anti-dengue vaccines.
Antigen targeting to DCs is an elegant approach to improve
vaccine efficiency that has been intensively investigated in the last
ten years. It is based on the generation of fusion antibodies that
target the antigen of interest to a specific DC surface receptor [29].
Different antigens have already been used in fusion with mAbs
that target different receptors. Such constructs targeted antigens
from different pathogens such as HIV [25,27,28], Epstein-Barr
virus [53], papillomavirus [54], Plasmodium sp. [23,55], Leishmania
major [26] and Yersinia pestis [42,43,45], among others. It is
important to note that to accomplish specific T and B cell
activation, the fusion mAbs must be administered in the presence
of DC maturation stimuli or the result is tolerance [22,23,28,34].
In the present study, the production of both fusion mAbs (aDEC-
NS1 and aDCIR2-NS1) was accomplished successfully and
resulted in the generation of antigens with preserved antigenicity
and enhanced immunogenicity for the antibody-dependent and T
cell-dependent (in the case of aDEC-NS1) immune responses.
Figure 4. Differences in the IgG subclasses but not in the
affinity of the anti-NS1 antibodies generated by the immuni-
zation with fusion mAbs or recombinant NS1 protein. Mice were
immunized as described in figure 3. (A) Fourteen days after the second
dose, anti-NS1 antibody titers for individual IgG subclasses were
measured by ELISA. Each bar represents the mean values 6 SD of the
antibody titers obtained for eight mice. Numbers above the bars
indicate the IgG1/IgG2a ratio obtained for each group. (B) Anti-NS1
antibodies affinity estimation by thiocyanate elution-based ELISA.
Pooled sera from eight mice/group were tested 14 days after the
administration of the second dose in the presence of different
concentrations of ammonium thiocyanate. Total binding (100%)
corresponds to the sera binding in the absence of ammonium
thiocyanate. Results are expressed as the mean 6 SEM of four distinct
experiments performed in duplicate.
doi:10.1371/journal.pntd.0002330.g004
Figure 5. Induction of cellular immune responses in mice
immunized with the recombinant aDEC-NS1 and aDCIR2-NS1
mAbs. Mice were immunized as described in figure 3 (n = 5/group).
Seven days after the administration of the second dose, mice were
euthanized and their splenocytes were plated in the presence or
absence of 1 mg/ml of recombinant NS1 protein or ovalbumin (OVA), as
a control. The number of IFN-c producing cells was detected by
ELISPOT and the bars represent the mean 6 SD of pooled animals
performed in triplicates. Numbers of IFN-c producing cells in the
absence of any stimulus were subtracted from the stimulated samples.
Data were analyzed by a one-way ANOVA followed by the post-test
HSD Tukey. *** Refers to p,0.01. Representative of 3 experiments.
doi:10.1371/journal.pntd.0002330.g005
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The use of poly (I:C) as the adjuvant in this study was based on
evidence showing that it is able to induce T and B cell immunity
when administered with either aDEC [27,42,56] or aDCIR2 [42]
fusion mAbs. However, the quality of the immune response seems
to be modulated by the receptor used in the targeting, with the
aDEC inducing a more Th1 type of response while the aDCIR2
induces multiple cytokines, including IL-4 [42]. In addition, poly
(I:C) was shown to be a superior adjuvant to elicit CD4+ T cell
immunity when used with an aDEC fusion mAb and compared to
other adjuvants, such as: MALP-2 (TLR2/TLR6 ligand),
Pam3Cys (TLR1/TLR2 ligand), LPS (TLR4 ligand), R-848
(TLR7/TLR8 ligand) or CpG ODN 1826 (TLR9 ligand). When
antibody production against the fused antigen was considered,
other adjuvants (LPS and R-848) performed similarly to poly (I:C)
[52]. In our system, the use of CpG ODN 1826 with either aDEC
or aDCIR2 fused to NS1 did not show significant differences in
antibody responses when compared to poly (I:C), while poly (I:C)
performed better in challenge experiments (unpublished data). In
addition, poly (I:C) already showed a good safety record when
used to induce type I interferon in cancer patients [57], and better
potency as an adjuvant for responses to a protein antigen in rhesus
macaques when compared to other agonists [54]. Rhesus
macaques were also immunized with poly (I:C) or with poly-
ICLC, a poly (I:C) analogue, which has been stabilized against
serum nucleases that are present in the plasma of primates,
together with aDEC fusion mAbs. Results showed induction of
specific antibodies and T cell responses [55,58].
As stated above, poly (I:C) has been mainly used together with
aDEC fusion mAbs. Its use together with aDCIR2 fusion mAbs
has been less documented [26,42]. A recent paper showed a very
Figure 6. Immunization with aDEC-NS1 mAb confers partial protection to a lethal challenge with the DENV2 NGC strain. Mice were
immunized as described in figure 3. Challenge was performed intracranially using 40 LD50 of the DENV2 NGC strain 20 days after the administration of
the second dose. Survival (A) and morbidity (B) were monitored daily for 21 days after the challenge. n = 8–10 mice/group. * Refers to p,0.05 when
compared to the aDCIR2-NS1, aDCIR2, aDEC and saline groups.
doi:10.1371/journal.pntd.0002330.g006
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high TLR3 expression on the surface of the CD8a+ DCs which
also express DEC205 [59]. However, to our knowledge, such
analysis has not been performed for the DCIR2+ DCs. So, we
cannot rule out the possibility that poly (I:C) is acting directly on
the DCIR2+ DCs nor the possibility that the poly (I:C) effect on
these cells is only bystander.
One interesting characteristic of the chimeric mAbs is that the
NS1 portion preserved features of the native virus protein. The
significant reduction in anti-NS1 antibody titers observed when
sera from immunized mice were incubated with boiled NS1
indicates that a fraction of the anti-NS1 antibodies recognized
conformational epitopes, confirming that the NS1 fused to the
mAbs presents a three-dimensional structure similar to the native
viral protein. In fact, the results suggested that targeting NS1 to
the DEC205+ DC population induced more anti-NS1 antibodies
with specificity to conformational epitopes. Similar results were
obtained when a plasmid encoding the NS1 in frame with the
human tissue plasminogen activator was used in immunization
protocols [16]. Under non-reducing conditions higher molecular
weight bands were formed by the chimeric mAbs suggesting that
multimers were also formed. It is well known that NS1 is normally
found in a dimeric conformation on the surface of infected cells
and forms hexamers upon secretion [60,61]. We believe that the
presence of multimers indicates that NS1 present in one antibody
could also be forming complexes with another NS1 from a second
antibody. Finally, to ensure that the binding of the fusion
antibodies to their respective receptors was not lost by the
multimer formation, we performed binding assays using either
CHO cells permanently transfected with the respective receptors
or freshly stained spleen derived DCs. A receptor specific and dose
dependent binding was obtained for both fusion antibodies,
indicating that the binding capacity of each antibody was
preserved.
Immunization of mice with either aDEC-NS1 or aDCIR2-NS1
elicited high titers of anti-NS1 antibodies. This effect was detected
after administration of only 2 doses (prime and boost) consisting of
5 mg of the fusion antibodies (equivalent to 1.74 mg of NS1).
Administration of 10 mg of recombinant NS1 together with poly
Figure 7. CD4+ and CD8+ T cells play important roles on the protective responses induced in mice immunized with the aDEC-NS1
mAb. Mice were immunized as described in figure 3. One day before the challenge, mice were intravenously injected with 100 mg of aCD4 or aCD8
purified antibodies to deplete the respective T cell populations. Survival (A) and morbidity (B) were monitored daily for 21 days after the challenge.
n = 8 mice/group. * Refers to p,0.05 when compared to the aDEC-NS1+aCD4 mAb, adjuvant and saline groups.
doi:10.1371/journal.pntd.0002330.g007
Targeting Dengue Antigens to Dendritic Cells
PLOS Neglected Tropical Diseases | www.plosntds.org 10 July 2013 | Volume 7 | Issue 7 | e2330
(I:C) induced higher anti-NS1 antibody titers when compared to
mice immunized with the fusion mAbs. However, in this case, the
amount of recombinant NS1 administered to the mice was 5.7
times higher than that administered within the fusion mAbs. Also,
when NS1 was used as a DNA vaccine, antibody titers were 10
times lower [16] than those obtained with the administration of
the fusion mAbs. The induction of high antibody titers was also
observed in other models using antigen targeting to different DC
populations [23,30,62]. Thus, the present results add further
evidence that fusion of target antigens to the aDEC and aDCIR2
mAbs, in conjunction with poly (I:C), have a powerful effect on the
generation of antigen-specific serum IgG responses far superior
than other ordinarily used vaccine adjuvants.
When IgG subclasses were detected in the groups immunized
with either aDEC-NS1 or aDCIR2-NS1, an approximately 10-
fold difference in the IgG1/IgG2a ratio was observed. This result
indicates that there are differences in the quality of the humoral
immune response when these receptors are targeted in the
presence of poly (I:C). Similar results were observed when
antibody subclasses against LcrV protein from Yersinia pestis and
LACK protein from Leishmania major were measured [26,42].
Interestingly, the IgG1/IgG2a ratio obtained when the animals
were immunized with the NS1 protein was similar to that obtained
with aDEC-NS1. As already mentioned previously, we cannot rule
out the possibility that some recombinant NS1 was taken up by the
DEC205+ DC population. Furthermore, contrary to what was
shown when NS1 was administered in the presence of other
adjuvants such as Alum, Freund’s adjuvant or detoxified heat-
labile toxin [14], the IgG1/IgG2a ratio was smaller than 1 when
poly (I:C) was used.
Besides humoral immunity, the contribution of T cell response
was also evaluated after immunization of mice with the two
chimeric mAbs. We found IFN-c producing NS1 specific T cells
mainly in mice immunized with the aDEC-NS1 mAb. The fine
specificity of such cells still needs to be evaluated using peptides
comprising different portions of the NS1 protein. In different
models already described, the administration of fusion mAbs in the
presence of DC maturation stimuli induced robust T cell
proliferation [29,63]. Also, models using transgenic T cells (either
in vitro or transferred in vivo) and antigen targeting to the DEC205+
or DCIR2+ DCs showed that both DC populations may drive
increases in CD4+ T cell proliferation [24,26,34].
In an attempt to verify if the induced anti-NS1 immune
response would confer protective immunological status, mice were
challenged with the DENV2 NGC strain. Interestingly, despite the
similar IgG titers observed in the groups immunized with both
fusion mAbs, partial protection and reduction in morbidity signs
were only seen in the group immunized with aDEC-NS1. The
recombinant NS1 immunized group showed an intermediate
protection level. Of note, we cannot exclude the possibility that the
DEC205+ DC population can process part of the recombinant
NS1 protein, accounting for some degree of protection. This
protection could be due to the pro-inflammatory T cell responses
elicited in these animals. However, we cannot rule out the
potential effect of the different IgG subclasses between the groups
immunized with aDEC-NS1 and recombinant NS1. The role of
CD4+ and CD8+ T cells was demonstrated when the depletion of
these cell populations increased mortality and morbidity. In terms
of morbidity, a more pronounced role for the CD4+ T cells was
observed. Previous work demonstrated that antigen targeting
especially to DEC205+ DCs provided protection in other models
[28,42,56,64]. However, to our knowledge, this is the first time
that directing an antigen to the DEC205+ DCs induces CD4+ and
CD8+ T cells that directly mediate protection.
Altogether the present study indicates that targeting the NS1
protein to the DEC205+ DC population is a promising alternative
for the development of dengue vaccines based on purified
recombinant proteins. Moreover, the fusion of additional dengue
antigens, such as the envelope protein or immunogenic domains
derived from it to the aDEC mAb may further improve the
protective immunity to the virus.
Supporting Information
Figure S1 Gating strategy for the evaluation of binding
of the fusion mAbs to the CD11c+CD8a+ or
CD11c+CD8a2 DC subsets. Splenocytes were stained on ice
with different mixtures of mAbs. Doublets and CD19+DX5+ cells
were excluded for further analysis. CD11c+MHCII+ were gated
and separated by the expression of CD8a+. Analysis was
performed on the CD11c+CD8a+ and CD11c+CD8a2 DCs.
The numbers inside the graphs represent the percent of gated cells.
(TIF)
Figure S2 Immunization with aDEC-NS1 mAb reduces
morbidity to a lethal challenge with the DENV2 NGC
strain. Mice were immunized as described in figure 3 and
challenged as described in figure 6. Signs of morbidity were
recorded as described in the materials and methods section. (A)
Morbidity degree obtained for each mouse on day 21 after
challenge for the experiment depicted in figure 6. (B) Same as in A
for experiment depicted in figure 7. n = 4–10 mice/group.
(TIF)
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